CO5690531A2 - Formas de administracion masticables, no comprimidas dosificadas individualmente - Google Patents

Formas de administracion masticables, no comprimidas dosificadas individualmente

Info

Publication number
CO5690531A2
CO5690531A2 CO06043842A CO06043842A CO5690531A2 CO 5690531 A2 CO5690531 A2 CO 5690531A2 CO 06043842 A CO06043842 A CO 06043842A CO 06043842 A CO06043842 A CO 06043842A CO 5690531 A2 CO5690531 A2 CO 5690531A2
Authority
CO
Colombia
Prior art keywords
individually
administration forms
compressed
weight
water
Prior art date
Application number
CO06043842A
Other languages
English (en)
Inventor
Vidal Jose Luis Fabregas
Carbonell Antoni Masso
Gonzalez Nuria Garcia
Coll Pere Guiro
Original Assignee
Almirall Prodesfarma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34610359&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5690531(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Prodesfarma Sa filed Critical Almirall Prodesfarma Sa
Publication of CO5690531A2 publication Critical patent/CO5690531A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1.- Formas de administración dosificadas individualmente no comprimidas que comprenden una composición de al menos una sustancia farmacéuticamente activa disuelta o dispersada en un material matriz que comprende una mezcla de al menos 0,2% en peso de gelatina, al menos un agente estabilizador y al menos un alcohol soluble en agua y/o agua como disolvente, siendo dicha composición plástica a temperatura elevada, caracterizadas porque:el agente estabilizador se selecciona del grupo formado por (i) ésteres de la glicerina y ácidos grasos y (ii) productos originados por la reacción de alcoholisis / esterificación de dichos ésteres de la glicerina y ácidos grasos con polietilenglicoles, y b. el agente estabilizador tiene un punto de fusión en el intervalo de 42° C a 63° C el agua está presente en una cantidad no superior al 46% en peso de la composición.2.- Formas de administración dosificadas individualmente no comprimidas, según la reivindicación 1, en las que el estabilizante está presente en una cantidad superior al 1 % en peso de la formulación.3.- Formas de administración dosificadas individualmente no comprimidas, según cualquiera de las reivindicaciones anteriores, caracterizadas porque están envasadas en blisters o cavidades preformadas a partir de láminas.4.- Formas de administración dosificadas individualmente no comprimidas según cualquiera de las reivindicaciones anteriores, porque comprenden más del 18% en peso de al menos una sustancia farmacéuticamente activa.5.- Formas de administración dosificadas individualmente no comprimidas, según cualquiera de las reivindicaciones anteriores, caracterizadas porque comprenden un antiácido.6.- Formas de administración dosificadas individualmente no comprimidas, según cualquiera de las reivindicaciones anteriores, caracterizadas porque comprenden al menos 10% en peso de la composición de al menos un alcohol soluble en agua y/o agua como disolvente.
CO06043842A 2003-11-10 2006-05-09 Formas de administracion masticables, no comprimidas dosificadas individualmente CO5690531A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200302612A ES2235626B1 (es) 2003-11-10 2003-11-10 Formas de administracion masticables, no comprimidas dosificadas individualmente.

Publications (1)

Publication Number Publication Date
CO5690531A2 true CO5690531A2 (es) 2006-10-31

Family

ID=34610359

Family Applications (1)

Application Number Title Priority Date Filing Date
CO06043842A CO5690531A2 (es) 2003-11-10 2006-05-09 Formas de administracion masticables, no comprimidas dosificadas individualmente

Country Status (25)

Country Link
US (1) US20070134318A1 (es)
EP (1) EP1682097B1 (es)
JP (1) JP4879021B2 (es)
KR (1) KR20060116821A (es)
CN (1) CN1878542A (es)
AR (1) AR048050A1 (es)
AT (1) ATE492270T1 (es)
AU (1) AU2004290517B2 (es)
BR (1) BRPI0416215A (es)
CA (1) CA2548615A1 (es)
CO (1) CO5690531A2 (es)
DE (1) DE602004030706D1 (es)
EC (1) ECSP066553A (es)
ES (2) ES2235626B1 (es)
IL (1) IL175285A (es)
MY (1) MY143793A (es)
NO (1) NO20062723L (es)
NZ (1) NZ546375A (es)
PE (1) PE20050488A1 (es)
RU (1) RU2369379C2 (es)
TW (1) TW200526266A (es)
UA (1) UA90253C2 (es)
UY (1) UY28586A1 (es)
WO (2) WO2005048975A1 (es)
ZA (1) ZA200602416B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089559A1 (en) 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
PT2061465E (pt) 2006-08-23 2013-07-15 Valeant Pharmaceuticals Int Derivados de 4-(n-azacicloalquil)anilidas como moduladores do canal de potássio
JP2010511052A (ja) 2006-11-28 2010-04-08 バレアント ファーマシューティカルズ インターナショナル カリウムチャネル調節因子としての１，４ジアミノ二環式レチガビンアナログ
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
EP2170282A4 (en) * 2007-06-27 2014-11-05 Hanmi Pharm Ind Co Ltd METHOD FOR PREPARING RAPID DISAGGREGATION FORMULATION FOR ORAL ADMINISTRATION AND APPARATUS FOR PREPARING AND PACKAGING THEREFOR
IL187159A0 (en) 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
WO2010013242A1 (en) 2008-07-29 2010-02-04 Alcobra Ltd. Substituted pyridoxine-lactam carboxylate salts
EP2238976B1 (en) * 2009-04-03 2012-06-27 Hexal AG Oral films comprising 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro- 1H-quinolin-2-one base or salts or hydrates thereof
CN102481291B (zh) 2009-06-25 2015-10-21 阿尔考布拉有限公司 用于治疗、减轻症状、缓解、改善和预防认知疾病、障碍或病症的方法
EA021368B1 (ru) * 2011-06-21 2015-06-30 Общество С Ограниченной Ответственностью "Консорциум-Пик" Препарат кардиопротекторного действия
CN105911057B (zh) * 2016-06-22 2018-10-19 扬州一洋制药有限公司 一种铝镁加混悬液的质量控制方法
CN113425694A (zh) * 2021-07-02 2021-09-24 杭州蚕宝生物技术有限公司 一种石斛生物碱口腔崩解片剂及其制备方法
US12053484B2 (en) 2021-10-29 2024-08-06 Medicated Chews, Llc Simethicone chewable composition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5645411A (en) * 1979-09-20 1981-04-25 Taiho Yakuhin Kogyo Kk Poultice
FR2515035A1 (fr) * 1981-10-26 1983-04-29 Rhone Poulenc Sante Nouvelle forme galenique solide pour administration par voie orale et son procede de fabrication
EP0409432A3 (en) * 1989-07-20 1991-12-11 Warner-Lambert Company Confectionery delivery system
US5433951A (en) * 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
JPH08319232A (ja) * 1995-03-22 1996-12-03 Takeda Chem Ind Ltd 粉粒状組成物
JPH0912463A (ja) * 1995-06-23 1997-01-14 Fujisawa Pharmaceut Co Ltd 口中咀嚼用製剤
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
US6171615B1 (en) * 1998-07-06 2001-01-09 Gattefoss{acute over (e)} Sustained release theophylline formulations, excipient systems and methods of production
US6060078A (en) * 1998-09-28 2000-05-09 Sae Han Pharm Co., Ltd. Chewable tablet and process for preparation thereof
US6652880B1 (en) * 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
KR100886668B1 (ko) * 2001-02-14 2009-03-04 지더블유 파마 리미티드 약학적 제제
US6692771B2 (en) * 2001-02-23 2004-02-17 Cima Labs Inc. Emulsions as solid dosage forms for oral administration

Also Published As

Publication number Publication date
KR20060116821A (ko) 2006-11-15
EP1682097B1 (en) 2010-12-22
JP4879021B2 (ja) 2012-02-15
NO20062723L (no) 2006-06-12
AU2004290517B2 (en) 2010-05-27
MY143793A (en) 2011-07-15
RU2369379C2 (ru) 2009-10-10
EP1682097A2 (en) 2006-07-26
WO2005048974A3 (en) 2006-02-23
NZ546375A (en) 2009-11-27
TW200526266A (en) 2005-08-16
ES2235626B1 (es) 2006-11-01
ECSP066553A (es) 2006-12-20
ES2235626A1 (es) 2005-07-01
AU2004290517A1 (en) 2005-06-02
CN1878542A (zh) 2006-12-13
RU2006120087A (ru) 2007-12-27
ZA200602416B (en) 2009-06-24
BRPI0416215A (pt) 2006-12-26
AR048050A1 (es) 2006-03-29
WO2005048974A2 (en) 2005-06-02
PE20050488A1 (es) 2005-08-24
WO2005048975A1 (en) 2005-06-02
US20070134318A1 (en) 2007-06-14
DE602004030706D1 (de) 2011-02-03
JP2007510690A (ja) 2007-04-26
UA90253C2 (ru) 2010-04-26
IL175285A0 (en) 2006-09-05
IL175285A (en) 2011-04-28
UY28586A1 (es) 2005-05-31
ES2358332T3 (es) 2011-05-09
CA2548615A1 (en) 2005-06-02
ATE492270T1 (de) 2011-01-15

Similar Documents

Publication Publication Date Title
CO5690531A2 (es) Formas de administracion masticables, no comprimidas dosificadas individualmente
KR880701544A (ko) 이온화 가능한 의약 제제용 용해 시스템
ES2829386T3 (es) Parche de administración transdérmica
AR110986A2 (es) Composiciones de ecteinascidina, formulaciones liofilizadas, método de preparación y uso
AR048033A1 (es) Composicion farmaceutica para moldear componentes que comprende copolimero de poli(met)acrilato, cubierta, conector o espaciador de capsula moldeado por inyeccion que tiene la composicion farmaceutica y forma de dosificacion farmaceutica de multicomponentes a partir de dicha composicion
CN101641091B (zh) 他米巴罗汀胶囊剂
AR045076A1 (es) Composicion de pelicula que se disuelve oralmente, pelicula multicomponente que se disuelve oralmente, uso de la composicion de pelicula y de la pelicula que se disuelve oralmente para preparar un medicamento, forma de dosificacion oral y procedimiento para preparar la composicion de pelicula que se
KR890001526A (ko) 경구용 서방성 아세트 아미노펜 제형 및 이의 제조방법
ATE424815T1 (de) Stabilisierte umkehr-mizellen-zusammensetzungen und ihre verwendung
ES2058109T3 (es) Un procedimiento para la preparacion de una composicion farmaceutica antimicrobiana topica.
ES2188656T3 (es) Composicion antiviral para la cicatrizacion de una herida que contiene un piruvato, un antioxidante, una mezcla de acidos grasos saturados y un compuesto antiviral.
ID26221A (id) Komposisi-komposisi farmasi yang dapat dijadikan gel
JP2007510690A5 (es)
FI813734L (fi) Farmaceutiska kompositioner
NZ596657A (en) Self micro-emulsifying oral pharmaceutical composition of hydrophilic drug and preparation method thereof
BR0011347A (pt) Preparações e formas de administração compreendendo um composto ativo de ácido instável
DE602004017705D1 (de) Zusammensetzungen mit alphahydroxy-säureester zur wirkstofffreisetzung und anwendungsverfahren dafür
JP2012214454A (ja) 外用剤キット
PE20001547A1 (es) Composiciones de betahistina de liberacion controlada
AR002972A1 (es) Pildoras que tienen una matriz farmaceutica que proporcionan un perfil apropiado de liberacion de la droga, composicion para la preparacion de dichamatriz, proceso para preparar dichas pildoras y formas de dosificacion de dicha composicion.
UY29403A1 (es) Composiciones farmacéutica sólida que comprende telitromicina.
BRPI0409918A (pt) composição farmacêutica na forma de um hidrogel para administração transdérmica de ingredientes ativos
AR093275A1 (es) Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos
JP2007161653A (ja) 軟カプセル剤皮膜組成物
WO2020018866A1 (en) Devices and methods for ultrasonic delivery of an agent within an oral cavity

Legal Events

Date Code Title Description
FC Application refused